Department of Pathology, Memorial Sloan-Kettering Cancer Center, New York, NY, USA.
Mod Pathol. 2011 Sep;24(9):1207-20. doi: 10.1038/modpathol.2011.80. Epub 2011 May 20.
Over the past few years several investigators have independently described unique low-grade renal epithelial neoplasms with clear cytoplasm, focal to diffuse papillary architecture, and occasional leiomyomatous stromal metaplasia that are not currently recognized in the World Health Organization classification of renal tumors. These tumors have been referred to by a variety of names including clear-cell papillary renal cell carcinoma and recently "clear-cell tubulopapillary renal cell carcinoma". On the basis of the available data, such tumors are positive for cytokeratin 7 (CK7) and carbonic anhydrase IX (CA9), while being negative for CD10, α-methylacyl-CoA racemase (AMACR), and TFE3. These tumors reportedly lack trisomies of chromosomes 7 and 17, deletions of 3p25, von Hippel-Lindau (VHL) gene mutations, and VHL promoter hypermethylation. Herein, we report on nine cases of this tumor emphasizing detailed studies of the VHL gene and hypoxia-inducible factor (HIF) pathway. Molecular studies performed included VHL mutational analysis, copy number changes assessed using single-nucleotide polymorphism arrays, and qRT-PCR for VHL mRNA expression. Immunohistochemical stains for markers of HIF pathway activation (HIF-1α, CA9, and glucose transporter-1 (GLUT-1)) as well as other relevant markers (CK7, CD10, AMACR, and TFE3) were performed. None of our tumors harbored VHL gene mutations, losses of chromosomal region 3p25, or trisomies of chromosomes 7 or 17. VHL mRNA was overexpressed in our tumors relative to normal renal tissue and clear-cell renal cell carcinoma. All cases showed strong co-expression of CK7, HIF-1α, GLUT-1, and CA9. No expression of TFE3, CD10, or AMACR was seen. The morphological, immunophenotypic, and molecular features of these unique low-grade tumors are sufficiently distinct to allow separation from other renal cell carcinoma subtypes. The co-expression of CA9, HIF-1α, and GLUT-1 in the absence of VHL gene alterations in clear-cell papillary renal cell carcinoma suggests activation of the HIF pathway by non-VHL-dependent mechanisms.
在过去的几年中,一些研究人员已经独立描述了具有独特低级别肾上皮肿瘤的独特低级别肾上皮肿瘤,具有清晰的细胞质,局灶性至弥漫性乳头状结构,偶尔发生平滑肌基质化生,目前在世界卫生组织肾肿瘤分类中未被认可。这些肿瘤已经被各种各样的名称所引用,包括透明细胞乳头状肾细胞癌和最近的“透明细胞管状乳头状肾细胞癌”。基于现有数据,此类肿瘤对细胞角蛋白 7(CK7)和碳酸酐酶 IX(CA9)呈阳性,而对 CD10、α-甲基酰基辅酶 A 消旋酶(AMACR)和 TFE3 呈阴性。据报道,这些肿瘤缺乏染色体 7 和 17 的三倍体、3p25 的缺失、von Hippel-Lindau(VHL)基因突变和 VHL 启动子超甲基化。在此,我们报告了 9 例该肿瘤,强调了对 VHL 基因和缺氧诱导因子(HIF)通路的详细研究。进行的分子研究包括 VHL 基因突变分析、使用单核苷酸多态性阵列评估的拷贝数变化,以及 VHL mRNA 表达的 qRT-PCR。还进行了用于 HIF 通路激活标志物(HIF-1α、CA9 和葡萄糖转运蛋白-1(GLUT-1))以及其他相关标志物(CK7、CD10、AMACR 和 TFE3)的免疫组织化学染色。我们的肿瘤均未携带 VHL 基因突变、3p25 染色体区域缺失或染色体 7 或 17 的三倍体。与正常肾组织和透明细胞肾细胞癌相比,VHL mRNA 在我们的肿瘤中过度表达。所有病例均显示 CK7、HIF-1α、GLUT-1 和 CA9 的强烈共表达。未见 TFE3、CD10 或 AMACR 的表达。这些独特低级别肿瘤的形态、免疫表型和分子特征足以使其与其他肾细胞癌亚型区分开来。在透明细胞乳头状肾细胞癌中,CA9、HIF-1α 和 GLUT-1 的共表达而 VHL 基因改变缺失表明 HIF 通路的激活是由非 VHL 依赖性机制引起的。